Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenacapavir + Teropavimab + Zinlirvimab in Virologically Suppressed Adults With HIV-1
NCT05729568Phase 2Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Anti-infectious Disease mAbs, Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of Teropavimab, zinlirvimab, lenacapavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started May 2023; status: active, not recruiting.
02
Drugs
Teropavimabzinlirvimablenacapavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05729568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05729568.